Epstein-Barr virus-transformed lymphocytes from patients with bullous diseases produce autoantibodies to cytokeratins

Jacqueline Viac, Jacqueline Paire, Claude Desgranges, Keiji Iwatsuki, Jean Thivolet

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Human cell lines obtained after Epstein-Barr virus transformation of lymphocytes from seven patients with bullous diseases (Bullous pemphigoid, Pemphigus) and five controls were screened for the production of autoantibodies against skin antigens. In five out of seven patients, the culture supernatants tested by indirect immunofluorescence on frozen sections of normal human skin and rabbit lip showed the production of autoantibodies with different specificities: basal epidermal cells, whole epidermis, Merkel cells, fibroblasts endothelial cells, etc. All autoantibodies were of IgM class and reacted with intracellular structures. Some of them were further tested by immunoblotting against epidermal keratins and were found to react with the main human epidermal keratins (56 to 67 kDa). In contrast, even when patients had circulating autoantibodies, no supernatant showed any reactivity against the antigens usually involved in these diseases, i.e., the dermoepidermal junction or the intercellular speces of epidermis. Supernatants from controls did not show any reactivity by immunofluorescence. The results demonstrated that human lymphoid cell lines obtained from patients with bullous diseases elicited the production of anti-intermediate filament autoantibodies known to occur spontaneously in normal patients. It is suggested that this phenomenon may be linked to the blistering conditions that provoke tissue destruction.

Original languageEnglish
Pages (from-to)277-284
Number of pages8
JournalClinical Immunology and Immunopathology
Volume39
Issue number2
DOIs
Publication statusPublished - 1986
Externally publishedYes

Fingerprint

Keratins
Human Herpesvirus 4
Autoantibodies
Lymphocytes
Epidermis
Merkel Cells
Antigens
Cell Line
Bullous Pemphigoid
Skin
Intercellular Junctions
Pemphigus
Intermediate Filaments
Frozen Sections
Indirect Fluorescent Antibody Technique
Lymphocyte Activation
Lip
Immunoblotting
Fluorescent Antibody Technique
Immunoglobulin M

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pathology and Forensic Medicine
  • Immunology

Cite this

Epstein-Barr virus-transformed lymphocytes from patients with bullous diseases produce autoantibodies to cytokeratins. / Viac, Jacqueline; Paire, Jacqueline; Desgranges, Claude; Iwatsuki, Keiji; Thivolet, Jean.

In: Clinical Immunology and Immunopathology, Vol. 39, No. 2, 1986, p. 277-284.

Research output: Contribution to journalArticle

Viac, Jacqueline ; Paire, Jacqueline ; Desgranges, Claude ; Iwatsuki, Keiji ; Thivolet, Jean. / Epstein-Barr virus-transformed lymphocytes from patients with bullous diseases produce autoantibodies to cytokeratins. In: Clinical Immunology and Immunopathology. 1986 ; Vol. 39, No. 2. pp. 277-284.
@article{40736e81ff7640ba837eb4ede7c81841,
title = "Epstein-Barr virus-transformed lymphocytes from patients with bullous diseases produce autoantibodies to cytokeratins",
abstract = "Human cell lines obtained after Epstein-Barr virus transformation of lymphocytes from seven patients with bullous diseases (Bullous pemphigoid, Pemphigus) and five controls were screened for the production of autoantibodies against skin antigens. In five out of seven patients, the culture supernatants tested by indirect immunofluorescence on frozen sections of normal human skin and rabbit lip showed the production of autoantibodies with different specificities: basal epidermal cells, whole epidermis, Merkel cells, fibroblasts endothelial cells, etc. All autoantibodies were of IgM class and reacted with intracellular structures. Some of them were further tested by immunoblotting against epidermal keratins and were found to react with the main human epidermal keratins (56 to 67 kDa). In contrast, even when patients had circulating autoantibodies, no supernatant showed any reactivity against the antigens usually involved in these diseases, i.e., the dermoepidermal junction or the intercellular speces of epidermis. Supernatants from controls did not show any reactivity by immunofluorescence. The results demonstrated that human lymphoid cell lines obtained from patients with bullous diseases elicited the production of anti-intermediate filament autoantibodies known to occur spontaneously in normal patients. It is suggested that this phenomenon may be linked to the blistering conditions that provoke tissue destruction.",
author = "Jacqueline Viac and Jacqueline Paire and Claude Desgranges and Keiji Iwatsuki and Jean Thivolet",
year = "1986",
doi = "10.1016/0090-1229(86)90091-7",
language = "English",
volume = "39",
pages = "277--284",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Epstein-Barr virus-transformed lymphocytes from patients with bullous diseases produce autoantibodies to cytokeratins

AU - Viac, Jacqueline

AU - Paire, Jacqueline

AU - Desgranges, Claude

AU - Iwatsuki, Keiji

AU - Thivolet, Jean

PY - 1986

Y1 - 1986

N2 - Human cell lines obtained after Epstein-Barr virus transformation of lymphocytes from seven patients with bullous diseases (Bullous pemphigoid, Pemphigus) and five controls were screened for the production of autoantibodies against skin antigens. In five out of seven patients, the culture supernatants tested by indirect immunofluorescence on frozen sections of normal human skin and rabbit lip showed the production of autoantibodies with different specificities: basal epidermal cells, whole epidermis, Merkel cells, fibroblasts endothelial cells, etc. All autoantibodies were of IgM class and reacted with intracellular structures. Some of them were further tested by immunoblotting against epidermal keratins and were found to react with the main human epidermal keratins (56 to 67 kDa). In contrast, even when patients had circulating autoantibodies, no supernatant showed any reactivity against the antigens usually involved in these diseases, i.e., the dermoepidermal junction or the intercellular speces of epidermis. Supernatants from controls did not show any reactivity by immunofluorescence. The results demonstrated that human lymphoid cell lines obtained from patients with bullous diseases elicited the production of anti-intermediate filament autoantibodies known to occur spontaneously in normal patients. It is suggested that this phenomenon may be linked to the blistering conditions that provoke tissue destruction.

AB - Human cell lines obtained after Epstein-Barr virus transformation of lymphocytes from seven patients with bullous diseases (Bullous pemphigoid, Pemphigus) and five controls were screened for the production of autoantibodies against skin antigens. In five out of seven patients, the culture supernatants tested by indirect immunofluorescence on frozen sections of normal human skin and rabbit lip showed the production of autoantibodies with different specificities: basal epidermal cells, whole epidermis, Merkel cells, fibroblasts endothelial cells, etc. All autoantibodies were of IgM class and reacted with intracellular structures. Some of them were further tested by immunoblotting against epidermal keratins and were found to react with the main human epidermal keratins (56 to 67 kDa). In contrast, even when patients had circulating autoantibodies, no supernatant showed any reactivity against the antigens usually involved in these diseases, i.e., the dermoepidermal junction or the intercellular speces of epidermis. Supernatants from controls did not show any reactivity by immunofluorescence. The results demonstrated that human lymphoid cell lines obtained from patients with bullous diseases elicited the production of anti-intermediate filament autoantibodies known to occur spontaneously in normal patients. It is suggested that this phenomenon may be linked to the blistering conditions that provoke tissue destruction.

UR - http://www.scopus.com/inward/record.url?scp=0022590926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022590926&partnerID=8YFLogxK

U2 - 10.1016/0090-1229(86)90091-7

DO - 10.1016/0090-1229(86)90091-7

M3 - Article

VL - 39

SP - 277

EP - 284

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 2

ER -